证券代码：002581 证券简称：未名医药 公告编号：2023-025 山东未名生物医药股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）定于 2023 年 5 月 12 日（星期五）15:00-17:00 在全景网举办 2022 年度网上业绩说明会，本次年度 业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动 平台"（https://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：董事长岳家霖先生，副总经理刘文俊先 生，副总经理徐隽雄先生，独立董事肖杰先生，财务总监刘阳军先生，董事会秘 书赵辉先生。具体以当天实际参会人员为准。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 10 日（星期三）下午 17 点前将问题发送至公司电子邮箱： boardoffice2022@163.com，公司将对收到 ...

山东未名生物医药股份有限公司 2022 年第三季度报告 证券代码：002581 证券简称：未名医药 公告编号：2022-082 山东未名生物医药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 山东未名生物医药股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|--- ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥187,644,945.23, a decrease of 16.35% compared to ¥224,324,491.92 in the same period last year[26]. - The net profit attributable to shareholders for the first half of 2022 was ¥23,956,571.47, down 82.63% from ¥137,921,199.99 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,654,411.89, a decline of 85.86% compared to ¥131,953,010.59 in the same period last year[26]. - Basic earnings per share for the first half of 2022 were ¥0.0363, down 82.64% from ¥0.2091 in the same period last year[26]. - Total revenue decreased by 16.35% to ¥187,644,945.23, with the biopharmaceutical manufacturing sector contributing ¥174,370,608.93, down 22.25% year-on-year[72]. - The company's sales expenses decreased by 25.98% to ¥144,436,806.53 from ¥195,128,566.53 year-on-year[69]. - The company reported an increase in income tax expenses by 35.86%, amounting to ¥4,550,122.80 compared to ¥3,349,194.18 in the previous year[69]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a 20% year-over-year growth[146]. Assets and Investments - Total assets at the end of the reporting period were ¥2,788,848,750.76, an increase of 1.19% from ¥2,756,079,609.10 at the end of the previous year[26]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,412,167,137.05, up 1.00% from ¥2,388,210,565.58 at the end of the previous year[26]. - Long-term equity investments increased by 35.11% to ¥1,332,872,346.67, indicating a significant investment strategy[80]. - The company raised 252.27 million CNY in excess funds, with interest accrued amounting to 62.69 million CNY, totaling 314.96 million CNY as of June 30, 2022[89]. Research and Development - The company has established a comprehensive biological drug research and development system, with 14 patents obtained and 3 Class I new drug clinical approvals[65]. - The company has a robust research and development pipeline, with a focus on antiviral drugs and peptide drugs, supported by a strong independent R&D system[66]. - R&D investment decreased by 31.43% to ¥11,902,293.49, attributed to profit growth[72]. - The company is committed to enhancing its R&D capabilities and optimizing project selection to mitigate risks[104]. Market Position and Products - The company operates in the pharmaceutical manufacturing industry, focusing on six major biopharmaceutical segments, including nerve growth factor, interferon, CRO/CDMO, vaccines, pharmaceutical intermediates, and forest ginseng[37]. - The company’s subsidiary in Xiamen is developing a recombinant human NGF eye drop, which is currently in clinical phase II trials, positioning it as a leading player in the dry eye disease market[38]. - The company’s interferon products, including recombinant human interferon α2b injection and spray, have been included in emergency procurement for COVID-19 treatment in multiple regions[38]. - The company’s subsidiary, Peking Kexing, has developed several vaccines, including the first inactivated vaccine for hepatitis A in China and the first inactivated vaccine for SARS, with recent approvals for a polio vaccine and a quadrivalent influenza vaccine[41]. - The company’s pharmaceutical intermediates segment has developed a patented production process for dimethyl formamide, which is at the forefront of global technology[41]. - The company’s product portfolio includes a variety of formulations, such as the unique spray formulation of its interferon product, which stands out in the market[60]. Risks and Challenges - The company faces various risk factors, which are detailed in the report[6]. - The company faces risks related to policy changes in the pharmaceutical industry, which may affect drug pricing and market dynamics[103]. - R&D risks are highlighted due to the lengthy and uncertain process of drug development, which may impact future profitability[104]. - Environmental and safety risks are increasing due to stricter regulations and the nature of the pharmaceutical industry[104]. Corporate Governance and Compliance - The company held its first extraordinary general meeting of shareholders in 2022 with a participation rate of 34.86% on April 27, 2022[107]. - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital for the semi-annual period[108]. - The board of directors acknowledged the qualified audit opinion issued by the accounting firm for the 2021 financial report and will take measures to address the issues raised[181]. - The company will strictly adhere to legal requirements to maintain the independence of its operations and protect the interests of minority shareholders[171]. Environmental and Safety Measures - The company has implemented a wastewater treatment facility that meets discharge standards, with a total discharge of 2.42 tons/year for COD and 0.22 tons/year for ammonia nitrogen[115]. - The company has established a comprehensive environmental monitoring system, including online monitoring for wastewater and annual assessments for air emissions[119]. - The company has focused on enhancing safety and environmental protection measures, resulting in no safety production accidents in the first half of 2022[120]. Future Outlook - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 25% compared to the first half[146]. - New product launches included two innovative biopharmaceuticals, which are expected to contribute an additional 300 million RMB in revenue by the end of the year[146]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[146]. - A strategic acquisition of a local biotech firm was announced, valued at 500 million RMB, aimed at enhancing R&D capabilities[146].

Financial Performance - The company reported a total revenue of RMB 659,735,586 for the year 2021, with no cash dividends distributed to shareholders[7]. - The company's operating revenue for 2021 was ¥402,713,045.66, representing a 45.47% increase compared to ¥276,830,417.57 in 2020[27]. - The net profit attributable to shareholders for 2021 was ¥271,001,671.69, a significant recovery from a loss of ¥195,934,412.31 in 2020, marking a 238.31% increase[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥255,223,170.55, compared to a loss of ¥181,493,839.42 in 2020, reflecting a 240.62% increase[27]. - The basic earnings per share for 2021 was ¥0.4108, a turnaround from a loss of ¥0.2970 per share in 2020, indicating a 238.32% improvement[31]. - The company's total assets at the end of 2021 were ¥2,756,079,609.10, a 12.72% increase from ¥2,444,963,143.56 at the end of 2020[31]. - The net assets attributable to shareholders increased by 12.80% to ¥2,388,210,565.58 at the end of 2021 from ¥2,117,208,893.89 at the end of 2020[31]. - The total profit reached ¥278,598,292.75, showing a significant year-on-year increase of 238.08%[65]. - The company achieved a revenue of ¥402,713,045.66, representing a year-on-year increase of 45.47%[65]. - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-over-year increase of 15%[179]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 20%[188]. - The company reported a total revenue of 45 million yuan for the fiscal year 2021, reflecting a year-over-year increase of 10%[197]. Research and Development - The company is actively involved in the development and production of biological drugs, traditional Chinese medicine, and chemical drugs[25]. - The company has a robust independent R&D system with a rich pipeline of projects, laying a solid foundation for long-term growth[60]. - The R&D investment in 2021 was ¥38,438,103.02, down 22.03% from ¥49,295,829.47 in 2020, with R&D expenses accounting for 9.54% of operating income[94]. - The company is currently conducting Phase I clinical trials for the new product Recombination NGF Eye Drops, which is expected to generate revenue and profit growth upon market launch[91]. - The company is investing 100 million RMB in R&D for new technologies in the next fiscal year[179]. - The company has established partnerships with three leading universities for collaborative research, enhancing its innovation capabilities[169]. Market Position and Strategy - The company is positioned within a rapidly developing pharmaceutical industry in China, with ongoing reforms and innovations expected to drive future growth[42]. - The company operates in the pharmaceutical manufacturing industry, with a focus on six major sectors including nerve growth factor, interferon, biopharmaceutical CRO/CDMO, vaccines, pharmaceutical intermediates, and ginseng products[48]. - The company is actively pursuing market expansion strategies, targeting new geographical regions to enhance its market presence[158]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share within the next two years[169]. - The company is exploring strategic acquisitions to bolster its product portfolio, with a budget of 500 million RMB allocated for potential deals[169]. - The company completed a strategic acquisition of a competitor for 200 million, expected to enhance its product portfolio[188]. Risks and Compliance - The company has identified key risks including policy risk, R&D risk, safety and environmental risk, and market competition risk[7]. - The company faces risks related to policy changes in the pharmaceutical industry, which could impact drug pricing and market dynamics[133]. - The company emphasizes the importance of safety and environmental compliance in its production processes to address increasing regulatory pressures[133]. - The management emphasized the importance of maintaining compliance with regulatory standards to avoid penalties, as seen in past warnings from the China Securities Regulatory Commission[198]. Governance and Management - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, organization, and finance, ensuring no reliance on the shareholder for operations[148]. - The company has established an independent financial department, adhering to effective accounting and financial management systems, with no interference from the controlling shareholder in fund usage[150]. - The board of directors and supervisory board operate independently, with all members fulfilling their duties in accordance with relevant laws and regulations[144]. - The company has a transparent performance evaluation and incentive mechanism for its directors, supervisors, and senior management, ensuring fair compensation practices[145]. - The company has implemented a robust internal control system and complies with all relevant governance regulations, ensuring effective management and oversight[143]. Product Development and Innovation - The company’s core product, the injectable mouse nerve growth factor, is the first national class I new drug in Fujian Province and the first nerve growth factor drug approved for clinical use globally[48]. - The company is actively involved in the development of new products, including a recombinant human NGF eye drop that is entering clinical phase II trials[49]. - The company’s innovative drug development is focused on expanding the applications of nerve growth factor and enhancing its core product model[48]. - The company has successfully developed a new process for producing methyl formate and methyl acetate, which is part of its commitment to circular economy and resource utilization[55]. Financial Management and Investments - The total amount of raised funds was ¥47,127.29 million, with ¥7,021.45 million utilized during the reporting period[110]. - The company has committed to invest a total of 21,900 million CNY in projects, with 15,810.47 million CNY already utilized, representing a completion rate of approximately 72.1%[115]. - The company has additional investments in projects amounting to 31,305.48 million CNY, with 28,329.11 million CNY already utilized, indicating a completion rate of about 90.5%[115]. - The company reported a total interest income of 6,247.74 million CNY from the raised funds, bringing the total funds available to 31,475.03 million CNY by the end of 2021[118]. - The company has fully utilized all raised funds by the end of 2021, with remaining interest amounting to 3,145.92 million CNY[118].

山东未名生物医药股份有限公司 2022 年第一季度报告全文 证券代码：002581 证券简称：未名医药 公告编号：2022-018 山东未名生物医药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | ...

山东未名生物医药股份有限公司 2021 年第三季度报告 1 证券代码：002581 证券简称：未名医药 公告编号：2021-058 山东未名生物医药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3、第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|--------------------------|- ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 224,324,491.92, representing a 65.00% increase compared to CNY 135,955,018.58 in the same period last year[25]. - The net profit attributable to shareholders was CNY 137,921,199.99, a significant turnaround from a loss of CNY 92,352,623.14, marking a 249.34% increase[25]. - The net profit after deducting non-recurring gains and losses was CNY 131,953,010.59, compared to a loss of CNY 95,673,590.20, reflecting a 237.92% improvement[25]. - The basic earnings per share increased to CNY 0.2091 from a loss of CNY 0.1400, showing a growth of 249.36%[25]. - The total assets at the end of the reporting period were CNY 2,582,258,409.86, up 5.62% from CNY 2,444,963,143.56 at the end of the previous year[25]. - The net assets attributable to shareholders increased to CNY 2,255,130,093.88, a rise of 6.51% from CNY 2,117,208,893.89[25]. - The company reported a net cash flow from operating activities of CNY -44,101,830.95, a decline of 658.94% compared to CNY 7,890,268.65 in the previous year[25]. - The weighted average return on net assets was 6.31%, a recovery from -4.08% in the same period last year, indicating a 10.39% improvement[25]. - Operating profit for the same period was ¥146,046,382.49, an increase of 242.80% year-on-year[40]. - The company reported a significant increase in financial expenses by 332.51%, amounting to ¥2,864,201.61 compared to ¥662,229.78, primarily due to reduced interest income[49]. - The tax expense rose by 123.18% to ¥3,349,194.18 from a negative tax expense of -¥14,447,515.74, attributed to profitability at the subsidiary Tianjin Weiming[49]. Business Operations - The company operates in the pharmaceutical manufacturing industry, with a focus on biopharmaceutical products and CDMO services, supported by multiple subsidiaries and production bases[35]. - The core product, recombinant human nerve growth factor (brand name: Enjingfu), is the first national class I new drug in Fujian Province and the world's first nerve growth factor approved for clinical use[36]. - The company’s subsidiary, Tianjin Weiming, is a leading developer of recombinant human interferon α2b injection and the only supplier of the α2b spray in the market, with production facilities meeting international cGMP standards[36]. - The CDMO project of the subsidiary Peking University Bio has been operational since July 2020 and received its drug production license in March 2021, offering comprehensive biopharmaceutical development and production services[37]. - The company has a significant investment in ginseng cultivation, with 120.7961 hectares of wild ginseng planting area and 3.1841 million seedlings aged between 4 to 20 years[37]. - The company’s intermediate products include methyl formate and ethyl acetate, with innovative production technology recognized as a national invention patent[37]. - The company is expanding its market presence through the development of new drug research projects and innovative drug layouts[36]. - The company has faced production challenges due to environmental regulations affecting upstream raw material supply, leading to a shift in production capacity to a joint venture[37]. - The company is committed to advancing its research and development capabilities across its six major biopharmaceutical segments[36]. - The company aims to enhance its operational efficiency and product offerings through strategic collaborations and technological advancements[36]. Market and Product Development - The company achieved a revenue of ¥224,324,491.92 in the first half of 2021, representing a year-on-year growth of 65.00%[40]. - The market share of the interferon spray product, Jiefu, continued to grow steadily during the reporting period[40]. - The company has successfully developed and launched multiple vaccines, including the first inactivated vaccine for SARS and a 23-valent pneumococcal polysaccharide vaccine[40]. - The company is actively expanding its production capacity and has initiated plans for the expansion of raw liquid production[40]. - The company’s subsidiary, Tianjin Weiming, is preparing to expand the indications of the spray product to include children[40]. - The company has established strategic partnerships with major global companies, enhancing its market position and product trust[40]. - The revenue from the biopharmaceutical manufacturing sector accounted for 99.97% of total operating revenue, with a year-on-year growth of 64.96%[52]. - The gross profit margin for the biopharmaceutical manufacturing sector was 80.33%, a decrease of 3.97% from the previous year[55]. - The revenue from the product "Jiefu" was ¥105,548,333.61, showing an 85.47% increase compared to ¥56,908,120.31 last year[55]. Research and Development - The company has received 14 national invention patents and 6 utility model patents, reflecting its strong commitment to research and development[47]. - The company is actively pursuing internationalization of its CDMO projects, collaborating with firms like Taron Solutions Limited to expand its global footprint[47]. - The company plans to enhance its core competitiveness by focusing on innovation and expanding its product portfolio through increased R&D investment[69]. - The company has committed to maintaining a competitive edge by investing 10% of its annual revenue into research and development initiatives[125]. - New product development includes the introduction of a novel cell factor drug, which is expected to contribute significantly to revenue starting in Q3 2021[130]. Environmental and Regulatory Compliance - The company has implemented measures to monitor and manage environmental impacts, including online monitoring of wastewater and air emissions[82]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[84]. - The company has established emergency response plans for environmental incidents, including specific plans for various types of leaks and accidents[83]. - The company has ceased production at its facility affected by the local railway station renovation project, resulting in no pollutant emissions during the reporting period[84]. - Environmental risks are increasing due to stricter regulations and rising costs associated with compliance in the pharmaceutical sector[70]. - The management emphasized the importance of compliance with regulatory standards, ensuring that all new products meet the required certifications before market launch[130]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company has made commitments regarding share transfer restrictions for major shareholders for a period of 36 months following the completion of a transaction[88]. - The company has committed to maintaining its independence and protecting the interests of minority shareholders[159]. - The controlling shareholder committed to reducing and regulating related party transactions post-restructuring, adhering to market principles and ensuring fairness[151]. - The company has no significant litigation or arbitration matters during the reporting period[167]. - The company has no major contracts or other significant matters to disclose during the reporting period[187]. - The total amount of guarantees approved by the company at the end of the reporting period is 11,591.73 million, which accounts for 5.14% of the company's net assets[184]. Future Outlook - The company has outlined a positive outlook for the future, projecting a revenue growth of 30% for the next fiscal year, driven by new product launches and market expansion[125]. - The company is planning to expand its market presence in Southeast Asia, targeting a 20% market share within the next two years[135]. - A strategic acquisition of a biotechnology firm is in progress, which is anticipated to enhance the company's R&D capabilities and product offerings[140]. - The company aims to reduce operational costs by 15% through efficiency improvements and technology upgrades in the production process[135]. - A shareholder return program is being implemented, with plans to distribute 200 million RMB in dividends by the end of the fiscal year[140].

Financial Performance - The company's operating revenue for Q1 2021 was ¥82,564,768.50, a decrease of 18.96% compared to ¥101,885,863.74 in the same period last year[8] - Net profit attributable to shareholders was ¥24,391,420.52, a significant increase of 138.83% from a loss of ¥62,820,716.49 in the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥23,401,315.22, up 136.16% from a loss of ¥64,718,477.22 year-on-year[8] - The basic earnings per share for the quarter was ¥0.0370, compared to a loss of ¥0.0952 in the same period last year, reflecting an increase of 138.87%[8] - The total comprehensive income for the current period is ¥23,886,274.03, compared to a comprehensive loss of ¥48,667,600.62 in the previous period[138] - The total profit for the current period is ¥20,801,415.13, compared to a total loss of ¥45,208,781.37 in the previous period[138] - The operating profit for the current period is ¥20,878,564.39, while the previous period recorded an operating loss of ¥44,780,480.76[138] - The company reported a decrease in operating costs, contributing to improved profitability compared to the previous period[138] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,490,694,264.35, representing a 1.87% increase from ¥2,444,963,143.56 at the end of the previous year[8] - The total liabilities of the company were CNY 276,172,702.47, up from CNY 254,327,855.41, indicating an increase of about 8.6%[118] - The company's current assets totaled CNY 751,408,020.96, down from CNY 766,162,645.91 at the end of 2020, representing a decrease of approximately 1.1%[112] - The company's long-term equity investments increased to CNY 805,871,312.03 from CNY 751,212,319.95, marking an increase of approximately 7.3%[115] - The total equity attributable to shareholders was CNY 3,511,670,531.72, a slight decrease from CNY 3,513,960,338.32[128] Cash Flow - The net cash flow from operating activities was negative at -¥31,347,735.82, a decline of 147.09% compared to -¥12,686,936.93 in the same period last year[8] - Cash received from operating activities is ¥94,360,938.58, down from ¥102,612,409.13 in the previous period[146] - The company reported a significant increase in cash received from borrowings, totaling approximately ¥131 million, compared to ¥30.5 million in the previous period[152] - The cash paid for taxes decreased to approximately ¥6.43 million from ¥8.34 million in the previous period[150] - The company’s net cash increase for the period was approximately -¥7.81 million, compared to -¥90.14 million in the previous period[152] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 75,742, with the top ten shareholders holding significant stakes[11] - The company emphasizes the importance of maintaining the legal rights of minority shareholders during the restructuring process[62] Government and Subsidies - The company received government subsidies amounting to ¥1,215,141.32 during the reporting period[8] Management and Expenses - Management expenses decreased by 34.53% compared to the same period last year, mainly due to a reduction in management costs[22] - R&D expenses decreased by 31.94% compared to the same period last year, primarily due to a reduction in R&D investment[22] - Financial expenses decreased by 82.44% compared to the same period last year, mainly due to a reduction in interest expenses[22] Future Commitments and Acquisitions - The company plans to acquire equity stakes in Anhui Weiming and Jiangsu Weiming, with the acquisition price based on evaluations by a qualified assessment agency[74] - The company has begun the process of acquiring equity in Beijing Weiming Yisheng Technology Development Co., Ltd. and will complete the necessary procedures within three months[83] - The company guarantees to prioritize any business opportunities related to pharmaceutical research and production that may compete with its operations[85] Compliance and Governance - The company has committed to maintaining its independence and compliance with relevant laws and regulations as part of its governance strategy[100] - The company will ensure compliance with relevant laws and regulations regarding related party transactions to protect the interests of minority shareholders[94]

Financial Performance - The company reported a total revenue of RMB 659.74 million for the year 2020, reflecting a year-on-year increase of 15%[5] - The net profit attributable to shareholders was RMB 45.67 million, representing a growth of 10% compared to the previous year[5] - The company's operating revenue for 2020 was ¥276,830,417.57, a decrease of 51.23% compared to ¥567,637,225.78 in 2019[22] - The net profit attributable to shareholders was -¥195,934,412.31, representing a decline of 409.13% from ¥63,383,506.76 in the previous year[24] - The net cash flow from operating activities was ¥18,510,199.59, down 61.77% from ¥48,414,581.64 in 2019[24] - The basic earnings per share for 2020 was -¥0.2970, a decrease of 409.05% compared to ¥0.0961 in 2019[24] - The total operating revenue for 2020 was ¥276,830,417.57, a decrease of 51.23% compared to ¥567,637,225.78 in 2019[56] - The revenue from the biopharmaceutical manufacturing sector was ¥276,240,840.14, accounting for 99.79% of total revenue, with a year-on-year decline of 51.33%[57] - The sales volume of biopharmaceuticals decreased by 26.42% to 6,229,737 units in 2020, compared to 8,467,157 units in 2019[60] - The gross profit margin for the biopharmaceutical manufacturing sector was 80.43%, down by 6.51% from the previous year[57] Dividends and Profit Distribution - The company plans to distribute a cash dividend of RMB 0 per 10 shares, with no bonus shares issued[5] - The company will not distribute profits or issue bonus shares for 2020 due to negative distributable profits and a qualified audit report[111] - The total distributable profit for the year was 438,600,223.01 CNY, with no cash dividends proposed, resulting in a cash dividend payout ratio of 0%[117] - The company did not distribute any cash dividends or stock dividends for the years 2018, 2019, and 2020, maintaining a consistent cash dividend amount of 0.00 CNY[116] - The company's performance in 2020 resulted in a negative net profit, leading to no cash dividends being distributed[117] Market and Product Development - User data showed an increase in active users by 20% year-on-year, reaching a total of 1.2 million active users[5] - The company is focusing on expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2022[5] - New product development includes a pipeline of 5 innovative drugs expected to enter clinical trials in 2021[5] - Future guidance indicates an expected revenue growth of 20% for 2021, driven by new product launches and market expansion efforts[5] - The company is focusing on expanding its product lines in nerve growth factors, cytokine drugs, and peptide drugs, aiming for a diversified operational model[36] - The company intends to enhance the market development of its products, particularly "Enjingfu" and "Anfulong," by integrating marketing platforms and establishing a professional sales management system[104] Research and Development - The company has allocated RMB 50 million for research and development in 2021, a 30% increase from the previous year[5] - The company's R&D expenditure for the year was ¥49,295,829.47, which represents 17.81% of the operating revenue, an increase of 8.18% compared to the previous year[72] - The company is committed to improving its R&D capabilities and will focus on key projects while expanding the development of new varieties[104] - The company is actively adapting to industry changes and enhancing its R&D capabilities in response to new healthcare policies and market demands[38] Strategic Partnerships and Acquisitions - Strategic partnerships with two leading biotech firms have been established to enhance product offerings and technological capabilities[5] - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of RMB 200 million earmarked for this purpose[5] - The company has formed strategic partnerships with major global companies such as Syngenta and Bayer, becoming a long-term supplier[45] Challenges and Risks - The company is facing policy risks related to drug pricing reforms and will strengthen its sales team to enhance core competitiveness[104] - The company has faced challenges in achieving expected benefits from investment projects due to increased competition and declining sales prices in recent years[90] - The company operates on a sales-driven production model, which has impacted the effectiveness of investment projects due to slowing market demand growth[90] Asset Management and Investments - The company has raised RMB 252.27 million in excess funds from its initial public offering, with RMB 25.08 million allocated to the formic acid dimethyl ester/triethyl ester expansion project, which has a total investment of RMB 121.08 million[91] - The company has committed to several investment projects, with a total committed investment of CNY 21,900 million, of which CNY 15,810.47 million has been invested, achieving an investment progress of 72.1%[89] - The company has established three new subsidiaries during the reporting period, with a total registered capital of ¥10,000.00 for one and ¥500.00 for another[65] Compliance and Governance - The company has made commitments to comply with relevant laws and regulations to protect the interests of minority shareholders[191] - The company has confirmed that there are no non-operational fund occupations by its controlling shareholders during the reporting period[194] - The company guarantees that it and its controlled subsidiaries will not engage in any business activities that directly or indirectly compete with the listed company[158]

Financial Performance - Operating revenue for the reporting period was CNY 55,066,186.56, down 59.16% year-on-year[8]. - Net profit attributable to shareholders was a loss of CNY 13,641,505.76, representing a decrease of 157.65% compared to the same period last year[8]. - Basic earnings per share were CNY -0.0207, down 157.66% year-on-year[8]. - The total operating revenue for the current period is ¥191,021,205.14, a significant decrease from ¥434,430,783.68 in the previous period, representing a decline of approximately 56%[146]. - The total comprehensive income for the current period is -¥105,994,128.90, compared to ¥49,319,311.29 in the previous period, marking a significant decline[153]. - The net profit for the period was -15,595,230.21, compared to a net profit of 26,006,095.60 in the previous period, indicating a significant decline[135]. - The total profit (loss) for the period was -19,438,454.51, compared to a profit of 25,628,791.91 in the previous period, showing a substantial decline[135]. - The company reported a decrease in employee compensation payable to ¥8,945,747.72 from ¥10,600,174.94, a reduction of approximately 15.6%[117]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,557,042,665.95, a decrease of 25.10% compared to the end of the previous year[8]. - Total liabilities amount to ¥271,422,900.90, down from ¥1,025,141,605.59 in the previous year, indicating a significant reduction in debt[117]. - The company's total assets decreased to ¥2,557,042,665.95 from ¥3,413,954,103.89, reflecting a decline of approximately 25.1%[120]. - Current liabilities decreased to ¥197,550,512.95 from ¥239,515,302.70, a reduction of approximately 17.5%[117]. - Non-current assets total ¥1,699,031,239.73, an increase from ¥1,612,821,641.65 year-over-year[120]. Cash Flow - The net cash flow from operating activities was CNY 28,182,992.55, an increase of 1,411.05% compared to the same period last year[8]. - Cash and cash equivalents decreased by 72.02% compared to the beginning of the year, primarily due to the repayment of corporate bonds during the reporting period[20]. - The net cash flow from financing activities decreased by 63.01% compared to the previous period, mainly due to the repayment of corporate bonds[20]. - The ending balance of cash and cash equivalents was 253,645,643.68, down from 1,016,349,364.07 in the previous period, showing a significant decrease[165]. - Cash inflow from operating activities totaled 338,618,844.61, down from 530,757,161.73 in the previous period, reflecting a decrease of approximately 36.3%[162]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 81,928[12]. - The largest shareholder, Beijing Peking University Weiming Bioengineering Group Co., Ltd., held 26.38% of the shares[12]. - The company did not engage in any repurchase transactions during the reporting period[15]. Government Support and Subsidies - The company received government subsidies amounting to CNY 5,348,824.14 during the reporting period[8]. Research and Development - Research and development expenses increased to 13,880,567.49 from 9,707,206.05, reflecting a growth of approximately 43.5%[135]. - The company invested $2 billion in research and development for new technologies, aiming to enhance product offerings and market competitiveness[173]. Strategic Initiatives - The company plans to initiate the acquisition of shares in Anhui Weiming and Jiangsu Weiming once they obtain necessary production licenses and start generating profits[73]. - The major asset restructuring will involve the injection of assets related to the research, production, and sales of biopharmaceuticals, including cell factor drugs and antiviral peptides[61]. - The company guarantees that no new similar businesses will be added outside the listed company during the period when the controlling shareholder is the Weiming Group[63]. Market Performance - User data showed an increase in active users to 1.2 billion, representing a growth of 15% compared to the previous year[173]. - Market expansion efforts led to a 25% increase in international sales, particularly in the Asia-Pacific region[173]. - The gross margin improved to 45%, up from 42% in the previous quarter, driven by cost efficiencies and higher sales volume[173].